NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP examines the adequacy of REGENXBIO, Inc.'s (NASDAQ: RGNX) risk disclosures to investors during the period between February 9, 2022 and January 27, 2026. Find out if you qualify to recover losses from inadequate disclosures. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. REGENXBIO shareholders lost $2.40 per share, a 17.8% single-day decline, after the FDA placed a clinical hold on RGX-111 following dis. ...

RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm Accessibility StatementSkip NavigationNEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required t ...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), of the important April 14, 2026 lead plaintiff deadline. SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), of the important April 14, 2026 lead plaintiff deadline. SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO, Inc. for allegedly misleading investors about the viability of its drug candidate RGX-111, which is intended for the treatment of MPS I [2][3]. Group 1: Class Action Details - The class action is on behalf of all investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [1]. - Allegations include that REGENXBIO misrepresented the safety and efficacy of RGX-111, despite knowing about serious safety issues, including the potential for CNS neoplasm [2][3]. - Following the announcement of a clinical hold by the FDA on RGX-111 due to a case of neoplasm, REGENXBIO's stock price dropped from $13.41 to $11.01, a decline of 17.8% in one day [3]. Group 2: Shareholder Actions - Shareholders interested in participating as lead plaintiffs must submit their papers by April 14, 2026 [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. Group 3: Company Background - REGENXBIO, Inc. is a clinical-stage biotechnology company focused on gene therapies that deliver functional genes to cells with genetic defects in the United States [1].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- F ...

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff deadline.SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026, of the April 14, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought REGENXBIO securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2026 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [4] - Defendants reportedly made positive assertions about RGX-111's trial success while concealing material adverse facts about its efficacy and safety [4] - The lawsuit claims that when the true details became public, investors suffered damages due to the misleading statements [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. due to alleged violations of federal securities laws related to misleading statements about the efficacy and safety of its RGX-111 trial study [2][3]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in REGENXBIO between February 9, 2022, and January 27, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against REGENXBIO, with a deadline of April 14, 2026, for investors to seek the role of lead plaintiff [2]. Group 2: Company Performance and Stock Impact - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to a case of neoplasm in a trial participant, which also affected RGX-121 for MPS II [4]. - Following this announcement, REGENXBIO's stock price dropped by $2.40 per share, or 17.9%, closing at $11.01 per share [4]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [3].

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/regenxbio-inc-loss-submission-form/?id=184362&from=3  CLASS PERIOD: February 9, 20 ...